Is Lamictal an Antidepressant or a Mood Stabilizer?

Lamictal (lamotrigine) is officially classified as a mood stabilizer and anticonvulsant, not an antidepressant. The distinction matters because it shapes how the drug is prescribed and what it’s approved for: maintenance treatment of bipolar disorder, with a particular strength in preventing the depressive side of the illness. But lamotrigine blurs the line between categories more than almost any other psychiatric medication, and its antidepressant-like effects in bipolar depression are a major reason clinicians reach for it.

Why the Label “Mood Stabilizer” Stuck

Lamotrigine started life as an epilepsy drug in the early 1990s. Its mood-stabilizing properties were noticed by accident: clinicians treating epileptic patients observed improvements in mood that couldn’t be explained by seizure control alone. That pattern of discovery, where a drug developed for one purpose turns out to help with something else entirely, has been formally described as a “type III” serendipitous finding in the history of bipolar treatments.¹

When lamotrigine was eventually studied for bipolar disorder, it earned approval specifically as maintenance therapy, meaning it’s used to keep people stable over the long term rather than to treat an acute episode. Early clinical trial data showed it was effective in treating and preventing bipolar depression without destabilizing mood, a critical distinction from traditional antidepressants, which can trigger manic episodes in bipolar patients.² That combination of depression prevention and mood stability is what earned it the “mood stabilizer” label rather than “antidepressant.”

How Lamotrigine Works Differently From Antidepressants

Most antidepressants, like SSRIs and SNRIs, work by increasing the availability of serotonin or norepinephrine in the brain. Lamotrigine does something completely different. It calms overactive neurons by affecting voltage-gated ion channels, which reduces how much of the excitatory chemical glutamate gets released. There’s also evidence that it enhances the brain’s inhibitory signaling system.³ In practical terms, lamotrigine turns down neural “noise” rather than boosting mood-related chemical messengers.

The glutamate reduction has been directly demonstrated in laboratory studies showing that lamotrigine progressively inhibits glutamate release through its action on sodium channels in nerve endings.⁴ This mechanism places it in the same pharmacological neighborhood as other anticonvulsants, not alongside the drugs we typically call antidepressants.

Animal research adds another layer. In rats modeling depression, lamotrigine reversed depressive behavior and restored levels of BDNF, a protein important for brain cell health and adaptation, in the amygdala.⁵ Several mood stabilizers and antidepressants share this ability to boost protective brain proteins, which may be part of why their clinical effects can overlap despite very different primary mechanisms.⁶

What Brain Imaging Reveals

One of the more compelling pieces of evidence for why lamotrigine helps with depression comes from brain imaging studies. When researchers used magnetic stimulation over the prefrontal cortex (the area involved in mood regulation and executive function), lamotrigine increased activation in limbic regions, the emotional processing centers of the brain. Valproate, another mood stabilizer used for bipolar disorder, had no such effect.⁷

Further imaging work showed that lamotrigine specifically strengthened the connection between the left dorsolateral prefrontal cortex and the anterior cingulate cortex, a circuit heavily implicated in depression. Valproate, again, did not do this.⁸ This helps explain why lamotrigine has antidepressant-like properties that other mood stabilizers lack: it appears to enhance prefrontal-to-emotional-brain communication in a way its class peers do not.

The Evidence for Bipolar Depression

Lamotrigine’s strongest evidence is in preventing the return of bipolar depressive episodes, not in treating acute depression that’s happening right now. A landmark 18-month trial compared lamotrigine, lithium, and placebo in patients with bipolar I disorder. Lamotrigine was better than placebo at delaying the return of depressive episodes, while lithium was better at delaying manic episodes.⁹ This complementary pattern is why some clinicians think of lamotrigine as the “depression side” counterpart to lithium’s “mania side” protection.

A meta-analysis of randomized trials confirmed the pattern: lamotrigine reduced the risk of depressive symptoms recurring by about 22% compared to placebo in bipolar maintenance, and also extended the time before symptoms reappeared.¹⁰ Long-term data also shows that lamotrigine treats bipolar depressive episodes without increasing cycling between mood states or provoking a switch into mania.¹¹

That said, manic switches are not impossible. Rare case reports exist of lamotrigine triggering mania, particularly in patients with rapid cycling bipolar disorder.¹² The literature on this is thin, consisting mostly of individual case reports rather than patterns seen in large trials, but it’s worth knowing that “mood stabilizer” doesn’t mean “impossible to destabilize.”

Does It Work for Regular Depression?

This is where the antidepressant question gets more complicated. Many people are prescribed lamotrigine off-label for unipolar depression, meaning depression without a bipolar diagnosis. The evidence here is considerably weaker and more mixed than the bipolar data.

A small randomized trial tested lamotrigine as an add-on to antidepressants in 34 patients with treatment-resistant major depression. The results showed no significant difference between lamotrigine and placebo on standard depression scales.¹³ The researchers noted that the study was small and the patients were particularly difficult to treat, which could explain the negative result. But it’s a reminder that the drug’s reputation as an antidepressant comes primarily from bipolar depression, not from major depressive disorder.

On the other hand, individual case reports describe striking responses. One case documented a patient with persistent depressive disorder (a chronic, low-grade form of depression) who failed three different antidepressants before improving markedly on lamotrigine.¹⁴ Case reports are the weakest form of evidence, of course, but they suggest that for some individuals, lamotrigine may do something that traditional antidepressants cannot. Whether that reflects an undiagnosed bipolar spectrum condition, a different depression subtype, or individual neurochemistry is still unclear.

Off-Label Use in Borderline Personality Disorder

Lamotrigine has gained a following among clinicians treating borderline personality disorder, a condition characterized by intense mood swings, emotional reactivity, and impulsive behavior. A comprehensive review found that lamotrigine shows promise for stabilizing mood and reducing emotional dysregulation and impulsivity in these patients, with a safety profile comparable to other available treatments.¹⁵

A controlled study of lamotrigine in borderline personality disorder found that patients taking it had significantly greater reductions in emotional instability and impulsivity compared to placebo, with the impulsivity finding being particularly strong.¹⁶ This use makes sense if you think of lamotrigine as a drug that smooths out mood variability rather than one that lifts mood in a single direction. It’s a mood stabilizer doing mood-stabilizer things, just in a population that isn’t bipolar.

The Cognitive Advantage

One reason lamotrigine is preferred over other mood stabilizers by many patients and clinicians is its effect on thinking and memory. Many psychiatric medications, especially other anticonvulsants used as mood stabilizers, can dull cognitive function. Lamotrigine appears to be an exception. A review of pharmacological approaches in bipolar disorder found that lamotrigine has a better cognitive profile than carbamazepine, valproate, topiramate, and zonisamide.¹⁷

A study comparing bipolar patients on lamotrigine to those on other anticonvulsants found that the lamotrigine group performed better on verbal fluency tasks, with preliminary evidence suggesting advantages in verbal memory as well.¹⁸ Even more encouragingly, a study of young patients with bipolar disorder found that lamotrigine treatment was associated with improvements in working memory and verbal memory over time.¹⁹ For people who feel cognitively blunted on lithium or valproate, this is a meaningful practical advantage.

The Slow Start and the Rash Risk

If your doctor has prescribed lamotrigine, you already know about the excruciatingly slow dose increase. Unlike antidepressants, which are typically started at or near their therapeutic dose, lamotrigine requires a gradual titration over several weeks. The reason is a serious but uncommon skin reaction: rashes leading to hospitalization, including Stevens-Johnson syndrome, occurred in roughly one in 300 adults in clinical trials and appeared to be linked to overly rapid dose increases and concurrent use of valproate.²⁰

The slow titration creates a practical problem that has nothing to do with pharmacology. Because the therapeutic effects of lamotrigine take weeks to emerge during the required dose increases, patients can feel like the medication isn’t doing anything. This can lead to requests to stop the drug before it has had a real chance to work.²¹ If you’re in the early weeks of lamotrigine and feel nothing, that’s expected. The drug needs time both for safety and for the dose to reach a level where it’s pharmacologically active.

Oral Contraceptives and Hormone Interactions

Lamotrigine has an interaction with estrogen-containing contraceptives that surprises many patients and, frankly, some prescribers. Estrogen speeds up the liver’s processing of lamotrigine, which can push blood levels down substantially. One study found a median drop of about 33% in lamotrigine levels during active oral contraceptive pill use compared to the placebo pill week.²²

The practical result is a seesaw effect: lamotrigine levels may drop into ineffective territory during the three weeks you’re taking active hormone pills, then rebound and potentially reach toxic levels during the placebo week. A review of the evidence describes this as “marked fluctuations” with real risks of both losing effectiveness and experiencing toxicity within a single monthly cycle.²³ If you take both medications, your prescriber may need to adjust your lamotrigine dose or recommend a different contraceptive approach. This interaction is well-documented and should be part of the initial conversation when lamotrigine is prescribed to anyone using hormonal birth control.

Lamotrigine During Pregnancy

For people with bipolar disorder who become pregnant, medication decisions are agonizing. Lamotrigine is one of the more studied mood-stabilizing medications in pregnancy, and the safety data is relatively reassuring. A prospective study comparing 218 lamotrigine-exposed pregnancies to unexposed pregnancies found similar rates of major birth defects between the two groups, and no cases of oral cleft in the lamotrigine group.²⁴ Early concerns about a possible link to cleft palate have not been consistently borne out in larger studies.

The bigger challenge is managing drug levels. Pregnancy dramatically changes how the body handles lamotrigine. Blood levels can swing wildly: in one study, lamotrigine concentrations jumped an average of 154% within five weeks of delivery compared to third-trimester levels, with some patients seeing increases as high as 640% postpartum compared to early pregnancy levels.²⁵ This means doses often need to be increased during pregnancy and then carefully reduced after delivery to avoid toxicity. The same study found that breast-fed infant blood levels averaged about a third of the mother’s levels, which is relevant for breastfeeding decisions.

Why the Category Question Matters in Practice

Whether lamotrigine is “really” an antidepressant or a mood stabilizer isn’t just a semantic argument. The classification drives prescribing decisions that directly affect patients. If lamotrigine were classified as an antidepressant, it would be used differently: prescribed for major depressive disorder without a bipolar diagnosis, titrated differently, and combined with other drugs according to antidepressant logic. As a mood stabilizer, it’s reserved primarily for bipolar spectrum disorders, where its specific strength lies in keeping depression at bay without destabilizing the other pole.

The classification also shapes insurance coverage and formulary placement. In many systems, using lamotrigine for unipolar depression requires a prior authorization because it’s off-label. A patient whose depression hasn’t responded to multiple antidepressants may face administrative barriers to trying lamotrigine precisely because the label says “mood stabilizer.” This is one of the more frustrating ways that neat pharmacological categories can collide with the messy reality of individual patient needs.

From a biological standpoint, lamotrigine probably doesn’t care what we call it. It modulates glutamate, strengthens prefrontal circuits, and protects neurons in ways that help some depressed patients whether or not they have a bipolar diagnosis. The drug occupies a gray zone between categories, and the honest answer is that our categories are rougher tools than the pharmacology warrants. It stabilizes mood. For many bipolar patients, the mood it stabilizes most effectively is the depressed one. Whether that makes it an antidepressant, a mood stabilizer, or something we don’t have a clean word for depends on how tightly you want to draw the lines.